Broad-Spectrum Anthelmintic Activity:
Eprinomectin effectively eliminates gastrointestinal nematodes (e.g., Haemonchus, Ostertagia, Cooperia), lungworms (Dictyocaulus viviparus), and other helminths. Clinical studies report >99% reduction in fecal egg counts and adult worm burdens post-treatment. Its sustained activity provides residual protection for up to 28 days, preventing reinfection during high-risk periods.
Ectoparasite Control:
The compound is highly effective against ectoparasites such as lice (Bovicola bovis), mange mites (Sarcoptes scabiei), and ticks (Rhipicephalus microplus). Topical application disrupts parasite life cycles by killing adults, larvae, and eggs, thereby reducing skin damage, anemia, and secondary infections in livestock.
Safety in Lactating Animals:
A key advantage of eprinomectin is its negligible transfer into milk due to high protein binding and rapid metabolism. This allows safe use in dairy cows without compromising milk quality or necessitating withdrawal periods, addressing a critical gap in parasite management for dairy operations.
Pharmacokinetic Advantages:
Eprinomectin's lipophilicity ensures prolonged tissue retention, maintaining therapeutic plasma concentrations for weeks. Its bioavailability via topical application exceeds 40%, surpassing older avermectins. The drug is metabolized in the liver to inactive compounds, which are excreted primarily in feces.